Tweet

Chad P. Bown

16 Jun, 10 tweets, 4 min read

https://twitter.com/helenbranswell/status/1405269082769747969

CureVac news is disappointing. But if it is not a viable vaccine, current constraints to global vaccine production raise an important POLICY QUESTION:

Can policymakers help Curevac reallocate its scarce supplies of vaccine-making inputs to help OTHER companies scale up? 🧵 1/10

https://twitter.com/helenbranswell/status/1405269082769747969

March: White House and European Commission set up a liaison between Jeffrey Zients and Thierry Breton to help overcome input shortages facing vaccine makers on both sides of the Atlantic... 2/10

politico.eu/article/eu-us-…

April: CureVac CEO complains about lack of access to inputs, blaming the Defense Production Act:

“Be it chemicals, equipment, filters or hoses: US manufacturers are obliged first to meet American demand, and that means we are slipping down the list” 3/10

reuters.com/business/healt…

May: policymakers help CureVac access inputs in short supply it needed to make vaccines:

“CureVac is grateful that with the help of the EU and U.S. officials, some critical issues could be resolved," the company said in a statement to Reuters... 4/10

reuters.com/world/us/eu-pe…

June: Now Curevac not only has scarce inputs on hand (“chemicals, equipment, filters or hoses”) to manufacture vaccines, but it has also reserved capacity that it may no longer need...

..including fill and finish by Fareva at a site in France... 5/10 curevac.com/en/2020/12/09/…

Novartis had also signed on to manufacture drug product at the Novartis Kundl, Austria site that might no longer be needed... 6/10

novartis.com/news/media-rel…

CureVac had also brought on board Celonic’s plant in Heidelberg, Germany to manufacture mRNA vaccine and lipids that might no longer be needed... 7/10

biopharminternational.com/view/celonic-g…

@TomBollyky

The need to now reallocate inputs and facilities - given shortages - was expected and something @TomBollyky and I explain to policymakers HERE... 8/10

piie.com/blogs/trade-an…

Yesterday, at the US-EU Summit, there was the announcement of a “Joint U.S.-EU COVID Manufacturing and Supply Chain Taskforce”

Dear Joint U.S.-EU COVID Manufacturing and Supply Chain Taskforce,

Please read this thread... 9/10

whitehouse.gov/briefing-room/…

*THIS* sort of reallocation of scarce vaccine inputs and manufacturing production capacity may get the world more COVID-19 vaccine doses faster than many other immediate-term policy initiatives being contemplated. ENDS/

• • •

Missing some Tweet in this thread? You can try to force a refresh

This Thread may be Removed Anytime!

Twitter may remove this content at anytime! Save it as PDF for later use!

More from @ChadBown

Chad P. Bown

@ChadBown

15 Jun

Monitoring COVID-19 vaccine input shortages: 🧵1/

Novavax said yesterday

"Now that borders are opening up, and all the manufacturers have been trying to increase their capacity- whether it's for filters, whether it's 2000 L bags or media...

This is an industry-wide problem.

...And we're getting better availability of product. It's still tight.

In normal times you would want six months worth of raw material inventory in a production plant, and we don't have that.

But we have weeks at least.

Before we had a week.

So it's getting better." 2/

Source: ir.novavax.com/events 3/

Read 4 tweets

Chad P. Bown

@ChadBown

7 Jun

@ChrisGHRogers

US government was accused of banning exports of vaccine-making supplies, most notably to India. New supply chain data reveals there was never a US export ban. But the episode highlights a problem demanding new policy.

My latest, with @ChrisGHRogers 🧵 1/
piie.com/blogs/trade-an…

India is being devastated by the pandemic right now. It needs more vaccines at home, and it needs equipment to make more vaccines for home... 2/

nytimes.com/article/india-…

Worse, Indian companies had also been expected to play a major role in providing billions of vaccine doses to poor countries globally through Covax.

Hopes were high as late as February 2021. By March, hopes were dashed, and the Serum Institute stopped exporting... 3/

Read 23 tweets

Chad P. Bown

@ChadBown

21 Apr

@Aime_Williams

VACCINES 🧵

1) Yes, policymakers & companies must address IP / tech transfer

2) But another bottleneck is how COUNTRIES cooperate to get vaccine manufacturing scaled up globally

Thanks @Aime_Williams for describing a proposal by @TomBollyky & me... 1/
ft.com/content/f230e4…

@TomBollyky

.@TomBollyky and I have proposed a Covid-19 Vaccine Investment and Trade Agreement (CVITA)... 2/

The problem to solve:

The vaccine manufacturing supply chain is complex.

(Reflexively we think "Big Pharma," but that is NOT reality for Covid-19 vaccines)

THIS supply chain is highly fragmented & requires considerable coordination to get ANY vaccines manufactured at all 3/

Read 7 tweets

Chad P. Bown

@ChadBown

18 Mar

@TomBollyky

Vaccine export restrictions and viral variants are the symptoms. The world is struggling to contain the COVID-19 pandemic. What to do?

Scale up 'Operation Warp Speed' globally, to get billions of doses to a world in need.

My latest, with @TomBollyky 1/
piie.com/blogs/trade-an…

"Woah!!!," you say.

Let me explain.

The development of several effective COVID-19 vaccines in less than a year is an historic achievement.

Hundreds of millions of doses have been manufactured and distributed in the United States.

The speed and scale is unprecedented...

2/

Yet, understanding the success of 'Operation Warp Speed' requires understanding the fragmented vaccine manufacturing supply chain.

LOTS of small companies. LOTS of critical inputs. LOTS of steps.

One missing input could grind the entire supply chain to a halt...

3/

Read 12 tweets

Chad P. Bown

@ChadBown

8 Feb

In late 2019, China agreed to buy tens of billions of dollars of additional US exports in 2020 under Trump's Phase One deal.

That didn't happen. Here’s why.

My latest 1/
piie.com/blogs/trade-an…

First, the good news.

China actually bought more from the US in 2020 than in 2019, including of those "phase one" products.

China even bought relatively more from the US of those goods than it bought from the rest of the world... 2/

But both comparisons are irrelevant for the LEGAL agreement. (Read the text.)

Under the threat of continued tariff escalation, Trump convinced Beijing in December 2019 to commit to an additional $200bn on top of *2017* trade flows—not 2019.

In 2020, China fell 41% short... 3/

Read 15 tweets

Chad P. Bown

@ChadBown

27 Jan

NEW: China’s purchases of US goods were over 40 percent short of its total commitment for 2020 found in the Phase One trade agreement.

Official December US export statistics released today, closing the book on US-China goods trade for 2020... 1/
piie.com/research/piie-…

The Phase One deal has 3 sectoral targets. Of those, China's purchases of US farm products were least bad. (Makes political sense)

According to US export statistics, China's purchases came up short in 2020 by
• 18% for agriculture
• 43% for manufacturing
• 63% for energy

2/

For #TradeTwitter, of interest is the sizeable GAP in farm purchases between Chinese import and US export statistics.

Ie, China's purchases of covered agricultural products reached 82% of target based on US export data BUT ONLY 64% based on Chinese import data. 🤔🤔🤔

3/

Read 5 tweets

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Share this page!

Chad P. Bown

Try unrolling a thread yourself!

More from @ChadBown

Chad P. Bown

Chad P. Bown

Chad P. Bown

Chad P. Bown

Chad P. Bown

Chad P. Bown

Did Thread Reader help you today?

Like this author's thread?